QS-Mirabegron
223673-61-8
C21h24n4o2s
800-126-3
Negotiable
Normal
>12 Months
Mirabegron
Mirabegron
>99%
Mirabegron
Mirabegron Powder
White Powder
White
Veterinary Grade
>99%
API
COA
HPLC
1.313
C21h24n4o2s
396.5059
138-140c
690c
396.16199719
QS-Mirabegron
Negotiable
>99%
Xian
Product Description
Pharmaceutical Intermediate Mirabegron Powder Mirabegron
| Product Name | Mirabegron |
| Appearance | Mirabegron Powder |
| Assay | >99% |
| MW | 396.5059 |
| MF | C21H24N4O2S |
| Melting point | 138-140C |
| Boiling point | 690C |
Urinary Incontinence: It can be used to manage urge incontinence, a type of incontinence where an urgent need to urinate leads to involuntary loss of urine.
Combination Therapy: Mirabegron may be used in combination with other therapies, such as anticholinergics, for patients who do not respond adequately to monotherapy.
- β3-Adrenoceptor Agonist Action: Mirabegron selectively binds to and activates β3-adrenoceptors in the bladder, resulting in smooth muscle relaxation and decreased contractility.
- Increase in Bladder Capacity: By relaxing the detrusor muscle, mirabegron increases bladder capacity and reduces the frequency of urination and urgency symptoms.
- Improvement in Quality of Life: Effective management of OAB symptoms with mirabegron can lead to significant improvements in patients' quality of life, reducing the impact of urinary symptoms on daily activities.
